Premium
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells
Author(s) -
I O Singer,
I. M. Franklin,
R E Clark,
Chalmers Ea,
SM Kelsey,
A. C. Newland,
Anne M. Sproul,
Gerard Crotty,
McCann,
AH Goldstone,
N McBride,
A Hepplestone,
William C. Watson,
R. A. Sharp,
P. Tansey
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00897.x
Subject(s) - medicine , idarubicin , peripheral blood stem cells , chronic myeloid leukaemia , haematopoiesis , cytarabine , chemotherapy , surgery , transplantation , stem cell , hematology , hematopoietic stem cell transplantation , biology , genetics
Forty‐three patients with chronic myeloid leukaemia in first chronic phase were recruited to study intensive chemotherapy (idarubicin plus cytarabine; IdAC) followed by collection of peripheral blood stem cells (PBSC) in the recovery phase. PBSC autografting was performed on 32 patients. One patient died during mobilization and three died following autograft. All procedural deaths occurred in patients who received IdAc more than a year from diagnosis. Nine further patients died, eight following progression of CML. 72% of transplanted patients showed a major cytogenetic response but most cases have returned to Philadelphia‐positive haemopoiesis. 62% of autografted patients remain alive (median survival from diagnosis 52 months). Four of the 11 patients who did not receive a transplant remain in chronic phase.